摘要
目的探讨多西他赛联合顺铂对宫颈癌(cervical carcinoma,CC)患者血清中肿瘤标志物,以及外周血免疫因子水平的影响。方法便利选择该院2019年1月—2021年1月收治的106例CC患者为研究对象,依据计算机随机数表方法分为观察组(n=53)和对照组(n=53)。对照组采用顺铂配合放化疗方案治疗,观察组在对照组基础上,加用多西他赛。比较两组患者血清中肿瘤标志物(CA125、CEA、SCCA)和免疫功能(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平以及治疗效果。结果治疗前,观察组CA125(51.15±2.29)U/mL、CEA(8.25±0.27)μg/L、SCCA(11.45±1.23)μg/L、CD3^(+)(53.07±1.73)%、CD4^(+)(32.61±0.73)%与对照组的CA125(51.13±1.68)U/mL、CEA(8.22±0.38)μg/L、SCCA(11.21±1.38)μg/L、CD3^(+)(53.21±1.93)%、CD4^(+)(32.73±0.71)%对比,差异无统计学意义(t=0.051、0.469、0.945、0.393、0.858,P>0.05);治疗后,观察组CA125(21.32±3.04)U/mL、CEA(2.73±1.87)μg/L、SCCA(3.39±1.31)μg/L、CD3^(+)(71.17±4.13)%、CD4^(+)(43.12±2.35)%、CD4^(+)/CD8^(+)(4.13±0.31)优于对照组的CA125(30.27±3.23)U/mL、CEA(4.88±1.38)μg/L、SCCA(6.53±1.28)μg/L、CD3^(+)(63.39±3.76)%、CD4^(+)(37.19±1.97)%、CD4^(+)/CD8^(+)(2.75±0.48),差异有统计学意义(t=14.690、6.735、12.481、10.141、14.078、17.582,P<0.05);观察组35例缓解,15例稳定,3例进展,总有效率为94.3%,对照组30例缓解,13例稳定,10例进展,总有效率为81.1%,观察组的总有效率显著优于对照组,差异有统计学意义(χ^(2)=4.300,P=0.038)。结论多西他赛联合顺铂方案对CC患者的治疗效果优于单一顺铂方案,且能降低肿瘤标志物水平,并改善放疗后的免疫功能,提高治疗效果。
Objective To investigate the effects of docetaxel combined with cisplatin on serum tumor markers and peripheral blood immune factor levels in patients with cervical cancer(CC).Methods Convenient selection of the hospital from January 2019 to January 2021,106 patients with CC who were admitted as the research object were divided into observation group(n=53)and control group(n=53)according to the computer random number table method.The control group was treated with cisplatin combined with radiotherapy and chemotherapy,and the observation group was treated with docetaxel on the basis of the control group.The serum levels of tumor markers(CA125,CEA,SCCA)and immune function(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))and the treatment effect were compared between the two groups of patients.Results Before treatment,the observation group had CA125(51.15±2.29)U/mL,CEA(8.25±0.27)μg/L,SCCA(11.45±1.23)μg/L,CD3^(+)(53.07±1.73)%,CD4^(+)(32.61±0.73)%and compared with the control group CA125(51.13±1.68)U/mL,CEA(8.22±0.38)μg/L,SCCA(11.21±1.38)μg/L,CD3^(+)(53.21±1.93)%,CD4^(+)(32.73±0.71)%,the difference was not statistically significant(t=0.051,0.469,0.945,0.393,0.858,P>0.05);after treatment,the observation group CA125(21.32±3.04)U/mL,CEA(2.73±1.87)μg/L,SCCA(3.39±1.31)μg/L,CD3^(+)(71.17±4.13)%,CD4^(+)(43.12±2.35)%,CD4^(+)/CD8^(+)(4.13±0.31)were better than the CA125(30.27±3.23)U/mL,CEA(4.88±1.38)μg/L,SCCA(6.53±1.28)μg/L,CD3^(+)(63.39±3.76)%,CD4^(+)(37.19±1.97)%,CD4^(+)/CD8^(+)(2.75±0.48),the difference was statistically significant(t=14.690,6.735,12.481,10.141,14.078,17.582,P<0.05);in the observation group,35 cases were relieved,15 cases were stable,3 cases progressed,and the total effective rate was 94.3%,30 cases in the control group were relieved,13 cases were stable,and 10 cases progressed,the total effective rate was 81.1%.The total effective rate of the observation group was significantly better than that of the control group,and the difference was statistically significant(χ^(2)=4.300,P=0.038).Conclusion The docetaxel combined with cisplatin regimen is better than the single cisplatin regimen in the treatment of CC patients,and it can reduce the level of tumor markers,improve the immune function after radiotherapy,and improve the therapeutic effect.
作者
黄文倩
HUANG Wenqian(Department of Pharmacy,Shanxian County Central Hospital,Heze,Shandong Province,274300 China)
出处
《中外医疗》
2021年第34期110-113,共4页
China & Foreign Medical Treatment
关键词
多西他赛
顺铂
宫颈癌
肿瘤标志物
免疫功能
Docetaxel
Cisplatin
Cervical cancer
Tumor markers
Immune function
